- $420.96m
- $132.77m
- $9.68m
Biotech firm Prothena's Q2 net loss narrows on lower expenses
Brief: Prothena Q2 Net Income USD -18.583 Million
Prothena Corporation PLC expected to post a loss of 39 cents a share - Earnings Preview
Prothena posts Q1 revenue surge fueled by $50 million Novo Nordisk milestone payment
Brief: Prothena Q1 Net Income USD 32.721 Million
Brief: Prothena Announces Novo Nordisk Obtains Fast Track Designation From The U.S. FDA For Coramitug
Prothena Q4 net loss narrows
Brief: Prothena Announces Poster Presentation On Its TDP-43 Cytope® Program At Neuroscience 2025
Prothena Q3 net loss narrows to $36.5 mln
Brief: Prothena Q3 Net Income USD -36.541 Million
Brief: Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation From US FDA For BMS-986446 For Treatment Of Alzheimer's Disease
Brief: Prothena Provides Update On PRX012 And Announces Results From The Phase 1 Ascent Clinical Program
Brief: Prothena Announces That Novo Nordisk Will Advance Coramitug Into Phase 3 Development
Prothena Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Brief: Prothena Q2 Net Income USD -125.767 Million
Brief: Prothena announces corporate restructuring
U.S. STOCKS ON THE MOVE- AMC,Natgas companies,Hologic
U.S. STOCKS ON THE MOVE-BellRing, Coeur, AMC Entertainment
U.S. STOCKS ON THE MOVE-Southwest Airlines, Informatica, Oklo